Get started
INOVIO PHARMACEUTIINOVIO PHARMACEUTIINOVIO PHARMACEUTI

INOVIO PHARMACEUTI

No trades
See on Supercharts
Overview Financials News
Ideas
Minds Forecast

GBM trade ideas

INO 1D 2 Month Larger TF shows continuation. Time/Space corrective until wave (B). Breakout of falling wedge finished. Retracement and continuation. Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
NASDAQ:INOShort
by TheCryptoChartWhisperer
3
Inovio is turning. INO? Wave A or something else. It is unclear what is forming in this picture exactly, but you can see the momentum shift in the candlesticks. Volatility and parabolism have both turned negative to add fuel to the fire. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NASDAQ:INOShort
by Rykin_Capital
INO What You're Thinking...INO finally broke back above the 786 fib line. Before the last bout of selling, you'll see this level was an area of support for the former penny stock. Now, thanks to some added excitement from delta news (the variant not the airline), INO shares are popping. They also jumped back above the 786 fib. Now the question is, will it rest the 618 fib like it tried to a few weeks ago? "Inovio Pharmaceuticals Inc. (NASDAQ: INO) has steadily climbed for the better part of the last 3 months thanks to recent pipeline progress. In June, the company had expanded its partnership with Advaccine Biopharmaceuticals Suzhou to conduct a Phase 3 segment of a trial called INNOVATE. The goal is to evaluate the safety and efficacy of the company’s INO-4800 in COVID patients. The treatment was already shown to be well tolerated and immunogenic in tested age groups in a Phase 2 study. This month Inovio announced that it and Advaccine received a regulatory allowance for 2 heterologous prime-boost clinical trials in China using INO-4800. “VID-19. If approved, we believe INO-4800 will be well-positioned to serve the vaccine needs of the global community as both a primary and a booster vaccine due to its tolerability, balanced cross-reactive immune responses, and strong thermostability profile that does not require cold or ultra-cold-chain transport,” said Dr. J. Joseph Kim, President, and CEO of INOVIO." Quote Source & Read more on INO: Former Penny Stocks To Watch After Merck’s ( MRK ) Latest FDA Win
NASDAQ:INO
by PennyStocks101
1
Inovio D1In May, Inovio said it would begin the study of INO-4800 in summer this year, after the vaccine candidate was found to be safe as well as well-tolerated and produced an immune response against the new coronavirus in a mid-stage clinical trial. read more The company started developing INO-4800 last year, but fell behind rivals after the U.S. Food and Drug Administration (FDA) put a part of the U.S. study on hold for more information on the vaccine delivery device. The FDA's decision was followed by the U.S. government pulling funding for the late-stage study, citing the fast-moving environment of vaccine development. The global trial will initially focus on Latin America, Asia Pacific and regions in Africa, the company said. "We were initially focusing on Latin America and Asia Pacific, but looking at the rapidly changing vaccination rates and the virus epidemiology, we are including regions in Africa," a company executive said during a post-earnings call on Monday. Inovio, which has no approved drug on the market, has so far received about $85 million in combined funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and the U.S. Department of Defense for the advancement and manufacture of INO-4800. Earlier this year, Inovio expanded a partnership with China's Advaccine Biopharmaceuticals to conduct the late-stage trial. Under the expanded deal, the companies expect to equally share its total cost.
NASDAQ:INOLong
by TradingForProfitPro